Check out our most popular compounded medications! Get Started
The Papaverine HCl 150 mg Slow Release (MEM4) Oral Capsules are meticulously crafted to provide a controlled and extended release of papaverine hydrochloride, utilizing Methocel E4M, a sophisticated controlled-release polymer. This formulation is specifically designed to maintain steady therapeutic levels of the medication in the bloodstream, thereby ensuring sustained efficacy over a prolonged period. The slow-release mechanism of these capsules allows for reduced dosing frequency, which can significantly enhance patient adherence to the treatment regimen.
Papaverine HCl is an opium alkaloid vasodilator agent, and in this slow-release form, it is indicated for the management of various conditions associated with vasospasms and smooth muscle spasms. These conditions include Erectile Dysfunction, Peripheral Vascular Disease, Vasospasm, Raynaud's Phenomenon, and Esophageal Spasms. By providing a gradual and consistent release of papaverine, these capsules help in alleviating symptoms associated with these disease states, improving patient quality of life.
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Papaverine HCl is a vasodilator that works by relaxing the muscles in blood vessels to help them dilate (widen). This formulation contains 150 mg of Papaverine HCl in a slow-release capsule, which is designed to provide a controlled and extended release of the medication. The use of Methocel E4M, a hydrophilic polymer, in these capsules allows for a gradual release of Papaverine HCl into the bloodstream, maintaining therapeutic levels over a longer period compared to immediate-release formulations. This can lead to improved patient adherence to the medication regimen due to the reduced frequency of dosing, as well as potentially decreased side effects due to more stable drug levels in the body.
The slow-release Papaverine HCl capsules are indicated for several conditions related to blood flow. In the treatment of erectile dysfunction, Papaverine HCl's vasodilatory effect helps increase blood flow to the penis, which can aid in achieving and maintaining an erection. For peripheral vascular disease, which is characterized by restricted blood flow to the extremities, Papaverine HCl can help improve blood circulation. In cases of vasospasm, where blood vessels spasm and narrow, the medication can help prevent or reduce the spasms, thus improving blood flow. Raynaud's Phenomenon, a condition where blood flow to fingers and toes is reduced, often in response to cold or stress, can also be managed with Papaverine HCl by mitigating the vasospastic episodes. Lastly, the medication can be used to alleviate esophageal spasms, which are painful contractions within the esophagus that can interfere with swallowing.
It is important for both patients and prescribers to understand that while this slow-release formulation of Papaverine HCl offers convenience and potential for better compliance, it must be used as directed to ensure safety and efficacy. The specific dosing regimen will depend on the individual patient's condition and response to therapy. As with any medication, there may be side effects, and patients should be counseled on what to expect and when to seek medical attention. For prescribers, it is crucial to consider the patient's overall health status, including kidney and liver function, which can affect drug metabolism and clearance.
If you have any questions or require further information about the Papaverine HCl 150 mg Slow Release (MEM4) Oral Capsules, please do not hesitate to reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is dedicated to providing comprehensive support and guidance to ensure optimal treatment outcomes for your patients.
Papaverine HCl is a vasodilator that works by relaxing the muscles in blood vessels to help them dilate (widen). This action can improve blood flow and is beneficial in treating conditions such as erectile dysfunction, peripheral vascular disease, vasospasm, Raynaud's phenomenon, and esophageal spasms. When considering the use of Papaverine HCl 150 mg Slow Release (MEM4) Oral Capsules, it is important to be aware of potential drug interactions that may affect the efficacy of the medication or increase the risk of adverse effects.
One significant interaction is with antihypertensive medications. Since papaverine is a vasodilator, it can enhance the effects of blood pressure-lowering drugs, potentially leading to hypotension. Patients taking antihypertensive medications should be monitored closely for signs of low blood pressure, such as dizziness or fainting, especially when starting or adjusting the dose of papaverine.
Phosphodiesterase inhibitors (PDE inhibitors), commonly used for erectile dysfunction, should be used with caution in combination with papaverine. The concurrent use of these medications can lead to additive vasodilatory effects and may increase the risk of priapism (prolonged and painful erection), hypotension, and other cardiovascular effects. Patients should be advised to report any prolonged erections to their healthcare provider immediately.
Patients on anticoagulant therapy, such as warfarin, should be aware that papaverine may potentiate the effects of these drugs, increasing the risk of bleeding. Regular monitoring of prothrombin time or INR is recommended, and dosage adjustments of the anticoagulant may be necessary.
Concomitant use of papaverine with other central nervous system depressants, including alcohol, benzodiazepines, and opioids, may result in additive sedative effects. Patients should be counseled to avoid or limit the use of alcohol and be cautious when taking other CNS depressants while on papaverine therapy.
Enzyme inducers, such as certain antiepileptics (e.g., phenytoin, carbamazepine) and antibiotics (e.g., rifampin), may decrease the plasma concentration of papaverine, potentially reducing its effectiveness. Conversely, enzyme inhibitors like some antifungals (e.g., ketoconazole) and antibiotics (e.g., erythromycin) may increase papaverine levels, leading to enhanced or prolonged effects and a higher risk of adverse reactions.
It is also important to note that the Methocel E4M polymer in the slow-release formulation of papaverine may interact with other oral medications by altering their absorption. Patients should be advised to take other oral medications at least 1 hour before or 2 hours after taking the slow-release papaverine to minimize potential interactions.
Given the complexity of drug interactions, prescribers should review the patient's complete medication profile for potential interactions before initiating therapy with Papaverine HCl 150 mg Slow Release (MEM4) Oral Capsules. Patients should be encouraged to report any new medications or changes in their medication regimen to their healthcare provider. Additionally, patients should be monitored for therapeutic efficacy and adverse effects throughout the course of treatment. If you have any questions or require further information regarding this formulation and its interactions, please reach out to us at Bayview Pharmacy.
Papaverine HCl is an opium alkaloid derivative that functions as a non-specific vasodilator, which means it relaxes blood vessels and increases blood flow. When formulated into 150 mg Slow Release (MEM4) Oral Capsules using Methocel E4M, the medication is designed to be released slowly and steadily into the bloodstream over an extended period. Methocel E4M is a type of hydrophilic polymer, also known as hypromellose, which forms a gel-like matrix in the presence of gastrointestinal fluids. This matrix creates a barrier through which the active ingredient, Papaverine HCl, must diffuse to be absorbed. As a result, the release of the drug is controlled, leading to a sustained therapeutic effect.
This controlled-release mechanism is particularly beneficial for conditions that require consistent blood levels of medication for relief or management. In the case of erectile dysfunction, Papaverine HCl works by dilating the blood vessels in the penis, which enhances blood flow and helps to achieve and maintain an erection. For peripheral vascular disease, vasospasm, and Raynaud's Phenomenon, the vasodilatory effects of Papaverine HCl improve blood flow to the affected extremities, reducing symptoms such as pain, cramping, and changes in skin color. Additionally, for esophageal spasms, the relaxation of smooth muscle can alleviate the discomfort and difficulty associated with swallowing.
The slow release formulation not only ensures a prolonged effect but also minimizes the potential for side effects that can occur with peak levels of immediate-release medications. It also reduces the dosing frequency, which can improve patient compliance, as taking medication less frequently is often more convenient and easier to remember.
It is essential for both patients and prescribers to understand that while the slow release formulation provides a steady therapeutic level of medication, it may take longer to see the initial effects compared to immediate-release forms. Therefore, it is important to follow the prescribed dosing schedule and not to adjust the dose or frequency without consulting a healthcare professional. If you have any questions about the Papaverine HCl 150 mg Slow Release (MEM4) Oral Capsules or how they work, please reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is here to provide the information and support you need.
Papaverine HCl 150 mg Slow Release (MEM4) Oral Capsules is a medication encapsulated with Methocel E4M, a controlled-release polymer. It is designed to gradually release the active ingredient, papaverine HCl, over an extended period, which provides sustained therapeutic effects.
Methocel E4M is a type of hydrophilic polymer that swells upon contact with gastrointestinal fluids, forming a gel-like matrix. This matrix controls the rate at which the active ingredient, papaverine HCl, is released from the capsule, ensuring a prolonged release profile for the drug.
The slow release formulation provides several benefits including sustained therapeutic effects, reduced dosing frequency, and improved patient compliance, particularly beneficial for medications that require a controlled and extended release in the body.
No, opening the capsule can compromise the controlled-release mechanism of the drug, leading to a rapid release of the active ingredient which may reduce the efficacy of the medicine and increase the risk of side effects.
The dosing frequency for Papaverine HCl Slow Release capsules should be determined by your healthcare provider, taking into account your specific condition and response to therapy. Due to its controlled-release design, dosing frequency may be less compared to immediate-release formulations.
The controlled-release formulation is designed so that the effects of the medication may last throughout the dosing interval. However, the exact duration of effect will depend on individual patient factors and the specific dosing schedule prescribed by your healthcare provider.
Whether Papaverine HCl Slow Release capsules should be taken with food or on an empty stomach will depend on the instructions provided by your healthcare provider. However, Methocel E4M should function independently of food intake.
If you miss a dose of Papaverine HCl Slow Release capsules, take it as soon as you remember. However, if it is nearly time for the next dose, skip the missed dose and resume your regular dosing schedule. Do not double the dose to catch up.
As with all medications, Papaverine HCl Slow Release capsules may cause side effects. Common side effects include digestive disturbance, headache, or an increase in liver enzymes. Contact your healthcare provider if you experience any severe or persistent side effects.
Store Papaverine HCl Slow Release capsules at room temperature, away from direct light, heat, and moisture. Keep the capsules out of reach of children and pets, and do not use them past the expiration date.
The safety of Papaverine HCl Slow Release capsules for use during pregnancy or breastfeeding is not well established. Please consult with your healthcare provider before taking this medication if you are pregnant or breastfeeding.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth
